Retina World Congress 2026 recap: Durability, diagnosis, discovery, and what’s next in retina care

On efficacy, Regillo said PDS “clearly outperforms” real-world anti-VEGF biologic injections over an extended time frame, with patients maintaining vision gains through the maintenance phase. On safety, most adverse events occurred around the time of surgery and became less frequent over time. “It’s comforting to know that we have 7 years of follow-up that we can tell patients what to expect having this device,” he said.